Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Malignant Neoplasm Intervention:   Procedure: Biospecimen Collection Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Every organ in the body is capable, to some extent, of repairing itself after an injury. As part of this process, scar tissue forms and then recedes to make room for normal tissue when healing is complete.However, when healing is disrupted — whether by chronic injury or disease — the cells that make up scar tissue can go rogue, continuously dividing and spreading until the scar eventually strangles the organ it was intended to help heal, which can lead to organ failure.That progressive, out-of-control scarring is called fibrosis, and it can occur in any organ in the body. Fibrosis plays a major role in many dis...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
The anti-leukemia activity of NK cells helps prevent relapse during hematopoietic stem cell transplantation (HSCT) in leukemia patients. However, the factors that determine the sensitivity or resistance of leukemia cells in the context of NK-mediated cytotoxicity are not well-established. Here, we performed a genome-wide CRISPR screen in the human chronic-myelogenous-leukemia (CML) cell line K562 to identify genes that regulate the vulnerability of leukemia cells to killing by primary human NK cells. The distribution of guide RNAs (gRNAs) in K562 cells that survived co-incubation with NK cells showed that loss of NCR3LG1, ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Preliminary results suggest that hematopoietic-stem-cell transplantation (HSCT) using UM171-expanded cord blood is feasible and safe in patients with hematological malignancy.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
Publication date: Available online 9 December 2019Source: Canadian Journal of CardiologyAuthor(s): Eli Muchtar, Grace Lin, Martha GroganAbstractLight chain (AL) amyloidosis is a systemic syndrome characterized by progressive organ dysfunction leading to organ failure and death. The heart is the most commonly involved organ and the leading determinant of short and long-term survival. Pathogenic free light chains, fragments of intact immunoglobulins, are the amyloidogenic protein and are secreted by clonal bone marrow plasma cells. The goal of therapy is to cut-off the supply of these pathogenic light chains to allow organ r...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
Authors: Zhang X, Tenerelli K, Wu S, Xia X, Yokota S, Sun C, Galvao J, Venugopalan P, Li C, Madaan A, Goldberg JL, Chang KC Abstract BACKGROUND: Glaucoma, the number one cause of irreversible blindness, is characterized by the loss of retinal ganglion cells (RGCs), which do not regenerate in humans or mammals after cell death. Cell transplantation provides an opportunity to restore vision in glaucoma, or other optic neuropathies. Since transplanting primary RGCs from deceased donor tissues may not be feasible, stem cell-derived RGCs could provide a plausible alternative source of donor cells for transplant. OBJ...
Source: Restorative Neurology and Neuroscience - Category: Neurology Tags: Restor Neurol Neurosci Source Type: research
TUESDAY, Dec. 10, 2019 -- Allogeneic hematopoietic stem cell transplantation (alloHSCT) performed after programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAB) treatment seems feasible for patients with...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
(NIH/National Cancer Institute) New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Multidisciplinary, cancer-specific geriatric assessment to create an individualized optimization plan appears to improve outcomes in older patients undergoing hematopoietic cell transplantation (HCT), researchers report.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Transplantation News Source Type: news
Bone Marrow Transplantation, Published online: 10 December 2019; doi:10.1038/s41409-019-0772-1Oral verruciform xanthoma associated with stem cell transplantation and graft versus host disease in a paediatric patient
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 10 December 2019; doi:10.1038/s41409-019-0770-3Immunogenicity of the inactivated influenza vaccine in children who have undergone autologous stem cell transplant
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Cancer & Oncology | Research | Stem Cell Therapy | Stem Cells | Transplants